Lilly releases higher dose Zepbound vials, reduces price for patients paying out of pocket. Meanwhile, the tirzepatide lawsuit heats up, with a potential ruing on preliminary injunction. The OFA strikes up a new battle with the FDA, suing them now over the end of the semaglutide shortage. 
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp 
📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4 
📖Paperback: https://amzn.to/4gAXrz4
💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP 
USE CODE "OTP10" to save 10%.
SOCIALS: 
📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 
🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&amp;_r=1 
👾: https://discord.gg/ZHeUh7WV 
📺: https://youtube.com/@ManOnTheMounjaro?feature=shared 
❌: https://x.com/manonthepen?s=21 
💻: https://www.onthepen.com

Lilly releases higher dose Zepbound vials, reduces price for patients paying out of pocket. Meanwhile, the tirzepatide lawsuit heats up, with a potential ruing on preliminary injunction. The OFA strikes up a new battle with the FDA, suing them now over the end of the semaglutide shortage.

Lilly Drops Zepbound Price, Compounders Sue FDA (again) OTP TWD 2.25.25